Improving the Pharmaceutical R&D Process: How Simulation Can Support Management Decision Making

Computer Applications in Pharmaceutical Research and Development

Volumn , Issue , 2006, Pages 247-273

  Chadwick, Andrew ^a   Moore, Jonathan ^b   Hupcey, Maggie A Z ^b   Purshouse, Robin ^c  

^a PA Consulting Group   (United Kingdom)

^b PA CONSULTING GROUP   (United States)

^c PA CONSULTING GROUP   (United Kingdom)

Author keywords

ARBITER tool in Bayesian network technology; Performance improvement challenge; Visualization and simulation application in management decision making

Indexed keywords

EID: 77954818426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470037237.ch11     Document Type: Chapter

References (25)

1. Ruffolo R. Re-engineering discovery and development: impact on the pharmaceutical industry of tomorrow. In: Drug Discovery Technology Europe 2005, IBC Life Sciences.
2. Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today August 2005;1031-9.
3. DiMasi JA New drug development in the United States from 1963-1999. Clin Pharmacol Therapeut May 2001;69:286-96.
4. DiMasi JA, Hansen RW, Grabowski HG The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
5. Luehrman, TA. What's it worth? A general manager's guide to valuation. Harvard Business Rev May-June 1997;132-42.
6. http://www.keyitsolutions.com/asp/rptdetails/report/46/cat/1296/
7. Nichols NA. Scientific management at Merck: an interview with CFO Judy Lewent. Harvard Business Rev January-February 1994;89-99.
8. Black F, Scholes M. The pricing of options and corporate liabilities. J Political Econ 1973;81:637-54.
9. Black, S. Letter to the Editor of The Economist (UK), 4 September 1999.
10. Gittins, J. Quantitative methods in the planning of pharmaceutical research. Drug Inform J 1996;30:459-87.
11. Palisade Corporation, Ithaca, NY (www.palisade.com).
12. Syncopation Software, London, UK www.syncopationsoftware.com
13. http://ondecidingbetter.editthispage.com/Tools
14. Burman C-F, Senn S. Examples of option values in drug development. Pharmaceut Statist 2003;2:113-25.
15. Schjødt-Eriksen J, Clausen J. Optimization and simulation in drug development-review and analysis http://www.imm.dtu.dk/pubdb/views/edoc_download.php/2834/ps/imm2834.ps
16. Wright T, Gillet VJ, Green DVS, Pickett SD. Optimising the size and configuration of combinatorial libraries. J Chem Info Comput Sci 2003;43:381-90.
17. Smith MK, Argyris C. Theories of action, double-loop learning and organizational learning. The encyclopedia of informal education, 2003; www.infed.org/thinkers/argyris.htm.
18. Tufte ER. The visual display of quantitative information, 2nd Ed. Graphics Press 2001.
19. Krumm FV, Rolle CF. Management and application of decision and risk analysis in DuPont. Interfaces 1992;22:84-93.
20. Subramanian D, Pekny JF, Reklaitis. A simulation-optimization framework for research and development pipeline management. AIChE J 2001;47(10): 2226.
21. Bertsekas D, Tsitsiklis J. Neuro-dynamic programming. Belmont, MA: Athena Scientific, 1996.
22. Blau G et al. Risk management in the development of new products in highly regulated industries. Comput Chem Eng 2000;24:659-64.
23. http://www.foresight.gov.uk/Intelligent_Infrastructure_Systems/long_paper.pdf
24. Pearl GM, Livingston-Carr S, Durham SK. Integration of Computations Analysis as a Sentinel Tool in Toxicological Assessments. Curr Topics in Med Chem 2001;1:247-55.
25. Chadwick A, Hajek M. Learning to improve the decision-making process in research. Drug Discov Today 2004;9(6): 251-7.